Sanofi abandons eczema drug approval efforts in another blow to OX40 class
Sanofi has chosen not to file for approval or continue the development of its immunology therapy, amlitelimab, in atopic dermatitis…
24 Jul 2026
BeOne to invest $300m in US manufacturing facility expansion
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US. The new investment increases BeOne…
24 Jul 2026
FDA grants fast track designation for Lundbeck’s Lu AH69593
Lundbeck has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational treatment, Lu AH69593, to treat narcolepsy. Lu AH69593 is an oral, small-molecule agonist…
23 Jul 2026
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro (zidesamtinib) having gained US approval in ROS1-positive non-small cell lung…
23 Jul 2026
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) orphan drug designation for AFTX-201, a treatment in development for BAG3-associated dilated cardiomyopathy (DCM). The gene therapy is under…
23 Jul 2026
Evogene and ELEO to develop new oral PCSK9 inhibitors
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular…
23 Jul 2026
Crystalys banks $130m to progress gout drug, plan for commercial readiness
Crystalys Therapeutics has secured $130m in a Series B raise to push its gout therapy, dotinurad, further down the pipeline, while gearing the drug up for commercialisation – potentially poising…